Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central anxious program, conolidine modulates alternate molecular targets. A Science Advancements examine identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://teimumuc307gxm4.wikiadvocate.com/user